News

News

Date Title and Summary Additional Formats
Toggle Summary "Non-systemic drugs: a critical review" published in Current Pharmaceutical Design
"Non-systemic drugs: a critical review" published in Current Pharmaceutical Design
View HTML
Toggle Summary Ardelyx Announces Closing of Public Offering Including Exercise of Underwriters' Right to Purchase Additional Shares
FREMONT, Calif. , Jan. 13, 2016 /PRNewswire/ -- Ardelyx, Inc. ( NASDAQ : ARDX), a clinical-stage biopharmaceutical company focused on gastrointestinal and cardio-renal diseases, today announced the completion of its previously announced underwritten public offering of 8,625,000 shares of its common
View HTML
Toggle Summary Ardelyx Announces Date of Second Quarter Financial Results and Presentation at Wedbush PacGrow Healthcare Conference
FREMONT, Calif. , Aug. 2, 2017 /PRNewswire/ --  Ardelyx, Inc. (NASDAQ: ARDX), a late-stage clinical company focused on enhancing the treatment of patients with cardiorenal and gastrointestinal (GI) diseases, today announced that management will host a conference call in conjunction with its second
View HTML
Toggle Summary Ardelyx Announces Full Exercise of Underwriters' Option to Purchase Additional Shares
FREMONT, Calif. , June 24, 2014 /PRNewswire/ --  Ardelyx, Inc. (Nasdaq: ARDX), a clinical-stage biopharmaceutical company focused on cardio-renal, GI and metabolic diseases, today announced the closing of its initial public offering of 4,928,900 shares of common stock at an initial public offering
View HTML
Toggle Summary Ardelyx Announces Initiation of Two Clinical Trials for RDX7675 for Treatment of Hyperkalemia
FREMONT, Calif. , Jan. 3, 2017 /PRNewswire/ -- Ardelyx, Inc. ( NASDAQ : ARDX), a clinical-stage company focused on enhancing the treatment of patients with gastrointestinal and cardiorenal diseases, today announced the initiation of a Phase 3 clinical trial and an onset-of-action clinical trial
View HTML
Toggle Summary Ardelyx Announces Presentation at Cowen and Company 37th Annual Healthcare Conference
FREMONT, Calif. , Feb. 27, 2017 /PRNewswire/ --  Ardelyx, Inc. (NASDAQ: ARDX), a late-stage clinical company focused on enhancing the treatment of patients with cardiorenal and gastrointestinal (GI) diseases, today announced that Mike Raab , chief executive officer of Ardelyx , will present at the
View HTML
Toggle Summary Ardelyx Announces Presentation at J.P. Morgan 35th Annual Healthcare Conference
FREMONT, Calif. , Jan. 3, 2017 /PRNewswire/ --  Ardelyx, Inc. ( NASDAQ : ARDX), a clinical-stage company focused on enhancing the treatment of patients with gastrointestinal and cardiorenal diseases, today announced that Mike Raab , chief executive officer of Ardelyx , will present a company
View HTML
Toggle Summary Ardelyx Announces Pricing of its Initial Public Offering
FREMONT, California – June 18, 2014 – Ardelyx, Inc.,  a clinical-stage biopharmaceutical company focused on cardio-renal, GI and metabolic diseases, today announced the pricing of its initial public offering of 4,286,000 shares of common stock at a public offering price of $14.00
View HTML
Toggle Summary Ardelyx Announces Pricing of Public Offering of Common Stock
FREMONT, Calif. , Jan. 7, 2016 /PRNewswire/ -- Ardelyx, Inc. ( NASDAQ : ARDX), a clinical-stage biopharmaceutical company focused on gastrointestinal and cardio-renal diseases, today announced the pricing of an underwritten public offering of 7,500,000 shares of its common stock at a public
View HTML
Toggle Summary Ardelyx Announces Proposed Public Offering of Common Stock
FREMONT, Calif. , Jan. 6, 2016 /PRNewswire/ --  Ardelyx, Inc. ( NASDAQ : ARDX), a clinical-stage biopharmaceutical company focused on gastrointestinal and cardio-renal diseases, today announced that it has commenced an underwritten public offering of up to $75,000,000 of shares of its common stock.
View HTML